Harrow Health, Inc. (HROW)
Automate Your Wheel Strategy on HROW
With Tiblio's Option Bot, you can configure your own wheel strategy including HROW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
These Analysts Revise Their Forecasts On Harrow Following Q4 Results
Published: March 04, 2026 by: Benzinga
Sentiment: Neutral
Harrow Inc. (NASDAQ: HROW) posted mixed results for the fourth quarter on Tuesday.
Read More
Harrow Shares Collapse, Another Opportunity?
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Harrow, Inc. remains a compelling long-term and trading opportunity, especially attractive in the mid-$30s and lower $40s after recent pullbacks. HROW delivered strong Q4 2025 revenue growth of 33% YoY to $89.1M, with annual sales up 36% and adjusted EBITDA up 54% to $61.9M. Key product lines IHEEZO and VEVYE posted record results, while TRIESENCE relaunch is in early growth stages and ImprimisRx revenue is intentionally shifting toward higher-margin products.
Read More
Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength?
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Read More
Harrow: Flirting With Missing 2025 Revised Guidance
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Negative
Harrow may deliver $265M in 2025 revenue, potentially missing the low end of its revised $270M–$280M guidance. Recent Bloomberg data suggest strong growth in Iheezo and Vevye, but specialty and compounded segments face headwinds and one-time impacts. Considerable uncertainty exists due to data limitations and ASP uncertainty.
Read More
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt's product candidates, MELT-210, MELT-300, and MELT-400, are based on the proprietary Zydis® ODT (oral dissolving tablet) drug delivery platform. The closing of the Melt acquisition marks a strategic expansion of Harrow's portfolio and reinforces its commitment to delivering innovative therapies that improve patient outcomes.
Read More
Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Harrow, Inc. ( HROW ) Q3 2025 Earnings Call November 11, 2025 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman of the Board Andrew Boll - President, CFO & Corporate Secretary Patrick Sullivan - Head of Commercial Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Thomas Shrader - BTIG, LLC, Research Division Lachlan Hanbury-Brown - …
Read More
Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Positive
Harrow, Inc. is an ophthalmology company with strong revenue growth, ambitious targets, and a diverse product portfolio including Vevye and Iheezo. HROW targets $280M in 2025 revenue and >$250M per quarter by Q4 2027, leveraging recent acquisitions and biosimilar partnerships. Despite low profitability and modest cash reserves, HROW's experienced management, robust pipeline, and expanding market share support a bullish long-term outlook.
Read More
Harrow: Buy A Blend Of Value And Growth
Published: September 12, 2025 by: Seeking Alpha
Sentiment: Positive
I'm bullish on Harrow due to the VEVYE Access for All program, which makes dry eye treatment affordable and drives strong prescription growth. VEVYE's discounted pricing addresses a massive, undertreated market, resulting in a 66% QoQ surge in prescriptions and rapid market penetration. Harrow's revenue growth is robust, averaging 43.7% YoY, with VEVYE expected to sustain momentum and push the company toward profitability.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
Published: August 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Best Momentum Stock to Buy for August 15th
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ECG, NVT and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2025.
Read More
Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Harrow (HROW) points to a 53.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript
Published: August 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Harrow, Inc. (NASDAQ:HROW ) Q2 2025 Earnings Call August 12, 2025 8:00 AM ET Company Participants Andrew R. Boll - CFO & Corporate Secretary Mark L.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
Published: July 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
Published: July 17, 2025 by: Business Wire
Sentiment: Neutral
INCHEON, Korea--(BUSINESS WIRE)-- #biosimilars--Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (Nasdaq: HROW), for Samsung Bioepis' ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTISi (ranibizumab) and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEAii (aflibercept) — in the United States. The commercial license will become effective upon com.
Read More
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
Published: July 17, 2025 by: Business Wire
Sentiment: Neutral
NASHVILLE--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter “Samsung Bioepis”) to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar refer.
Read More
Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar?
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Harrow: Immense Upside Potential
Published: July 09, 2025 by: Seeking Alpha
Sentiment: Positive
Harrow, Inc. is a strong swing trade in the $20s, with long-term upside as sales and new product launches drive sustained profits. Recent licensing of BYQLOVI and the VEVYE Access for All program are major catalysts, positioning VEVYE as a future top revenue product. Q1 results were mixed, with revenue growth but margin pressure; strategic shifts aim to boost branded product margins and long-term profitability.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
Published: July 07, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Harrow: Epic Growth & Operating Leverage On Full Display
Published: May 28, 2025 by: Seeking Alpha
Sentiment: Positive
Harrow has successfully leveraged its compounding pharmacy roots to drive rapid branded drug growth. Revenue has grown at a steady 40% CAGR for a decade & EBITDA has grown even more sharply. Management is guiding for this to not only continue, but actually accelerate. Harrow's operating leverage is plainly evident in the data. EBITDA margins have risen sharply as the company has grown, and management has guided for this to accelerate in 2025.
Read More
What Recession? I'm Swimming In Dividends
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
What Recession? I'm Swimming In Dividends
Read More
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.
Published: April 24, 2025 by: PRNewsWire
Sentiment: Neutral
BERWYN, Pa. , April 24, 2025 /PRNewswire/ -- Nordic Pharma, Inc., a subsidiary of Nordic Group B.V.
Read More
Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Harrow, Inc. (NASDAQ:HROW ) Q4 2024 - Earnings Conference Call March 28, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Thomas Flaten - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann and Company Mayank Mamtani - B. Riley Securities Yi Chen - H.
Read More
About Harrow Health, Inc. (HROW)
- IPO Date 2007-09-28
- Website https://www.harrowinc.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mark L. Baum
- Employees 382